Bortezomib-based chemotherapy in mantle cell lymphoma

Affiliations

¹ University of Plymouth Medical School and Department of Haematology, Plymouth University NHS Trust, Plymouth, PL6 8DH, UK. Electronic address: simon.rule@nhs.net.

Comment

Simon Rule. Lancet Oncol. 2018 Nov.

. 2018 Nov;19(11):1419-1421.

doi: 10.1016/S1470-2045(18)30743-5. Epub 2018 Oct 19.

¹ University of Plymouth Medical School and Department of Haematology, Plymouth University NHS Trust, Plymouth, PL6 8DH, UK. Electronic address: simon.rule@nhs.net.

No abstract available

Comment on

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.